Skip to content
Clinical Trials – home

Find therapies in clinical trials near you

recruiting
3 975
countries
28
conditions
2 106

10 trials match your criteria

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Arsenic Trioxide

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Neoplasm

Recruiting

Study on the Safety and Efficacy of Tretinoin with Radiation Therapy for Patients with Oligometastatic Solid Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tretinoin

Acne

Recruiting

Study Comparing Isotretinoin with Doxycycline, Tretinoin, and Adapalene for Moderate Acne in Patients with Skin of Color

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Adapalene

Acne

Recruiting

Study on the Effectiveness and Safety of Clindamycin and Tretinoin Gel for Patients with Papulopustular Acne

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Clindamycin

Study on Decitabine, Venetoclax, and Tretinoin for Patients with Acute Myeloid Leukemia Who Cannot Have Induction Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo

Acne

Not recruiting

Study on the Effectiveness of Clindamycin and Tretinoin Gel for Treating Acne in Patients

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Clindamycin

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.